Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
E G M van Geffen, J M A Langhout, S J A Hazen, T C Sluckin, S van Dieren, G L Beets, R G H Beets-Tan, W A A Borstlap, J W A Burger, K Horsthuis, M P W Intven, A G J Aalbers, K Havenga, A W K S Marinelli, J Melenhorst, J Nederend, H M U Peulen, H J T Rutten, W H Schreurs, J B Tuynman, C Verhoef, J H W de Wilt, C A M Marijnen, P J Tanis, M Kusters, On Behalf Of The Dutch Snapshot Research Group
BACKGROUND: In the Netherlands, use of neoadjuvant radiotherapy for rectal cancer declined after guideline revision in 2014. This decline is thought to affect the clinical nature and treatability of locally recurrent rectal cancer (LRRC). Therefore, this study compared two national cross-sectional cohorts before and after the guideline revision with the aim to determine the changes in treatment and survival of LRRC patients over time. METHODS: Patients who underwent resection of primary rectal cancer in 2011 (n = 2094) and 2016 (n = 2855) from two nationwide cohorts with a 4-year follow up were included...
March 20, 2024: European Journal of Cancer
#22
JOURNAL ARTICLE
Julia K Winkler, Katharina S Kommoss, Ferdinand Toberer, Alexander Enk, Lara V Maul, Alexander A Navarini, Jeremy Hudson, Gabriel Salerni, Albert Rosenberger, Holger A Haenssle
IMPORTANCE: Total body photography for skin cancer screening is a well-established tool allowing documentation and follow-up of the entire skin surface. Artificial intelligence-based systems are increasingly applied for automated lesion detection and diagnosis. DESIGN AND PATIENTS: In this prospective observational international multicentre study experienced dermatologists performed skin cancer screenings and identified clinically relevant melanocytic lesions (CRML, requiring biopsy or observation)...
March 19, 2024: European Journal of Cancer
#23
JOURNAL ARTICLE
Rikke B Holmstroem, Sidsel Pedersen, Rebecca Jurlander, Kasper Madsen, Marco Donia, Christina H Ruhlmann, Henrik Schmidt, Charlotte A Haslund, Lars Bastholt, Inge Marie Svane, Eva Ellebaek
BACKGROUND: Clinical trials have demonstrated promising outcomes for adjuvant immunotherapy in patients with resected melanoma. Real-life data provide valuable insights to support patient guidance and treatment decisions. METHODS: Observational population-based study examining a national cohort of patients with resected stage III-IV melanoma referred for adjuvant therapy. Data were extracted from the Danish Metastatic Melanoma Database (DAMMED). RESULTS: Between November 2018 and January 2022, 785 patients received adjuvant anti-PD-1...
March 19, 2024: European Journal of Cancer
#24
JOURNAL ARTICLE
Anna-Liesa Filbert, Leontien Kremer, Ruth Ladenstein, Catherine Chronaki, Alexander Degelsegger-Márquez, Heleen van der Pal, Edit Bardi, Anne Uyttebroeck, Thorsten Langer, Monica Muraca, Adela Cañete Nieto, Jelena Rascon, Francesca Bagnasco, Stefan Beyer, Jeroen Te Dorsthorst, Samira Essiaf, Antonio Orduña Galan, Anita Kienesberger, Kylie O'Brien, Marisa Correcher Palau, Saskia M F Pluijm, Sonia di Profio, Davide Saraceno, Carina Schneider, Günter Schreier, Justas Trinkūnas, Igor Zamberlan, Desiree Grabow, Riccardo Haupt
BACKGROUND: Childhood cancer survivors (CCS), of whom there are about 500,000 living in Europe, are at an increased risk of developing health problems [1-6] and require lifelong Survivorship Care. There are information and knowledge gaps among CCS and healthcare providers (HCPs) about requirements for Survivorship Care [7-9] that can be addressed by the Survivorship Passport (SurPass), a digital tool providing CCS and HCPs with a comprehensive summary of past treatment and tailored recommendations for Survivorship Care...
March 19, 2024: European Journal of Cancer
#25
REVIEW
Daniel L Hertz, Markus Joerger, Yung-Jue Bang, Ron H Mathijssen, Caicun Zhou, Li Zhang, David Gandara, Michael Stahl, Bradley J Monk, Ulrich Jaehde, Jan H Beumer
Paclitaxel, one of the most frequently used anticancer drugs, is dosed by body surface area, which leads to substantial inter-individual variability in systemic drug exposure. We evaluated clinical evidence regarding the scientific rationale and clinical benefit of individualized paclitaxel dosing based on measured systemic concentrations, known as therapeutic drug monitoring (TDM). In retrospective studies, higher systemic exposure is associated with greater toxicity and efficacy of paclitaxel treatment across several disease types and dosing regimens...
March 19, 2024: European Journal of Cancer
#26
JOURNAL ARTICLE
Thomas Wagner, Birgitte Grønkær Toft, Jakob Lauritsen, Mikkel Bandak, Ib Jarle Christensen, Birte Engvad, Michael Kreiberg, Mads Agerbæk, Lars Dysager, Andreas Carus, Josephine Julie Rosenvilde, Daniel Berney, Gedske Daugaard
BACKGROUND: Approximately 30% of patients with clinical stage I non-seminoma (CSI-NS) relapse. Current risk stratification is based on lymphovascular invasion (LVI) alone. The extent to which additional tumor characteristics can improve risk prediction remains unclear. OBJECTIVE: To determine the most important prognostic factors for relapse in CSI-NS patients. DESIGN, SETTING, AND PARTICIPANTS: Population-based cohort study including all patients with CSI-NS diagnosed in Denmark between 2013 and 2018 with follow-up until 2022...
March 17, 2024: European Journal of Cancer
#27
LETTER
Michael Lam, Timothée Olivier, Alyson Haslam, Jordan Tuia, Vinay Prasad
No abstract text is available yet for this article.
March 16, 2024: European Journal of Cancer
#28
LETTER
Stefano H Byer, Colten Stewart, Shareef Mansour, Udhayvir S Grewal
No abstract text is available yet for this article.
March 16, 2024: European Journal of Cancer
#29
JOURNAL ARTICLE
Rémy Barbe, Younes Belkouchi, Yves Menu, Romain Cohen, Clemence David, Michele Kind, Sana Harguem, Lama Dawi, Joya Hadchiti, Fatine Selhane, Nicolas Billet, Samy Ammari, Ambroise Bertin, Littisha Lawrance, Baptiste Cervantes, Antoine Hollebecque, Corinne Balleyguier, Paul-Henry Cournede, Hugues Talbot, Nathalie Lassau, Thierry Andre
BACKGROUND: This retrospective study determined survival responses to immune checkpoint inhibitors (ICIs), comparing mono- (mono) and combo-immunotherapy (combo) in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) by analyzing quantitative imaging data and clinical factors. METHODS: One hundred fifty patients were included from two centers and divided into training (n = 105) and validation (n = 45) cohorts...
March 16, 2024: European Journal of Cancer
#30
JOURNAL ARTICLE
Stylianos Tzedakis, Alexandre Challine, Sandrine Katsahian, David Malka, Romain Jaquet, Ugo Marchese, Martin Gaillard, Romain Coriat, Alix Dhote, Vincent Mallet, Heithem Jeddou, Karim Boudjema, David Fuks, Andrea Lazzati
BACKGROUND: Although the incidence of BTC is raising, national healthcare strategies to improve care lack. We aimed to explore patient clinical care pathways and strategies to improve biliary tract cancer (BTC) care. METHODS: We analysed the French National Healthcare database of all BTC inpatients between January 1, 2017 and December 31, 2021. Multinomial logistic regression adjusted odds ratios (aOR) were used to identify healthcare organisation factors that influenced access to curative care both overall and in a longitudinal sensibility analysis using optimal matching and hierarchical ascending classification to detect a subgroup of curative-care patients with a high survival over a two-year period...
March 16, 2024: European Journal of Cancer
#31
JOURNAL ARTICLE
Zoltán Lippai, Bálint Péterfia, Gergő Papp, Katalin Dezső, Gábor Bedics, Zsuzsanna Pápai, Meindert H Lamers, Rosan Cm Kuin, Károly Szuhai, Zoltán Sápi
INTRODUCTION: Dedifferentiated liposarcoma (DDLPS) is a common form of liposarcoma with challenging treatment modalities. Pan-TRK immunopositivity can be often observed without NTRK gene fusion in soft tissue sarcomas with myogenic differentiation. Expression and the role of NTRK in DDLPS are under-studied. We sought to identify activating mutations of the NTRK genes. MATERIALS AND METHODS: 131 DDLPS patients were selected for pan-TRK immunohistochemistry and positive cases were analyzed by Sanger sequencing for NTRK1, NTRK2 and NTRK3 genes...
March 14, 2024: European Journal of Cancer
#32
REVIEW
Gael S Roth, Loic Verlingue, Matthieu Sarabi, Jean-Frédéric Blanc, Emmanuel Boleslawski, Karim Boudjema, Anne-Laure Bretagne-Bignon, Marine Camus-Duboc, Romain Coriat, Gilles Créhange, Thierry De Baere, Christelle de la Fouchardière, Clarisse Dromain, Julien Edeline, Maximiliano Gelli, Boris Guiu, Samy Horn, Valérie Laurent-Croise, Côme Lepage, Astrid Lièvre, Anthony Lopez, Sylvain Manfredi, Julie Meilleroux, Cindy Neuzillet, Valérie Paradis, Frédéric Prat, Maxime Ronot, Olivier Rosmorduc, Antonio Sa Cunha, Olivier Soubrane, Anthony Turpin, Christophe Louvet, Olivier Bouché, David Malka
INTRODUCTION: This document is a summary of the French intergroup guidelines of the management of biliary tract cancers (BTC) (intrahepatic, perihilar and distal cholangiocarcinomas, and gallbladder carcinomas) published in September 2023, available on the website of the French Society of Gastroenterology (SNFGE) (www.tncd.org). METHODS: This collaborative work was conducted under the auspices of French medical and surgical societies involved in the management of BTC...
March 13, 2024: European Journal of Cancer
#33
JOURNAL ARTICLE
Joseph J Sacco, Richard Jackson, Pippa Corrie, Sarah Danson, T R Jeffry Evans, Sebastian Ochsenreither, Satish Kumar, Andrew Goodman, James Larkin, Ioannis Karydis, Neil Steven, Paul Lorigan, Ruth Plummer, Poulam Patel, Eftychia Psarelli, Anna Olsson-Brown, Heather Shaw, Serge Leyvraz, Louise Handley, Charlotte Rawcliffe, Paul Nathan
AIMS: The MAPK pathway is constitutively activated in uveal melanoma (UM). Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM. Pre-clinical studies support synergistic cytotoxic activity for MEK inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib and paclitaxel. PATIENTS AND METHODS: Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel...
March 11, 2024: European Journal of Cancer
#34
REVIEW
Hildur Helgadottir, Alexios Matikas, Josefin Fernebro, Jan-Erik Frödin, Simon Ekman, Kenny A Rodriguez-Wallberg
The treatment landscape of solid tumors has changed markedly in the last years. Molecularly targeted treatments and immunotherapies have been implemented and have, in many cancers, lowered the risk of relapse and prolonged survival. Patients with tumors harboring specific targetable molecular alterations or mutations are often of a younger age, and hence future fertility and family building can be important concerns in this group. However, there are great uncertainties regarding the effect of the new drugs on reproductive functions, including fertility, pregnancy and lactation and how young patients with cancers, both women and men should be advised...
March 11, 2024: European Journal of Cancer
#35
JOURNAL ARTICLE
A Thomas-Joulié, S Tran, L El Houari, A Seyve, F Bielle, C Birzu, F Lozano-Sanchez, K Mokhtari, M Giry, Y Marie, F Laigle-Donadey, C Dehais, C Houillier, D Psimaras, A Alentorn, A Laurenge, M Touat, M Sanson, K Hoang-Xuan, A Kas, L Rozenblum, M-O Habert, L Nichelli, D Leclercq, D Galanaud, J Jacob, C Karachi, L Capelle, A Carpentier, B Mathon, L Belin, A Idbaih
BACKGROUND: Glioblastoma (GBM) is the most common devastating primary brain cancer in adults. In our clinical practice, median overall survival (mOS) of GBM patients seems increasing over time. METHODS: To address this observation, we have retrospectively analyzed the prognosis of 722 newly diagnosed GBM patients, aged below 70, in good clinical conditions (i.e. Karnofsky Performance Status -KPS- above 70%) and treated in our department according to the standard of care (SOC) between 2005 and 2018...
March 11, 2024: European Journal of Cancer
#36
JOURNAL ARTICLE
Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, Giuseppe Maglietta, Paola Bordi, Emilio Bria, Emanuele Vita, Francesco Gelsomino, Andrea De Giglio, Alain Gelibter, Marco Siringo, Francesca Mazzoni, Enrico Caliman, Carlo Genova, Federica Bertolini, Giorgia Guaitoli, Francesco Passiglia, Marco Donatello Delcuratolo, Michele Montrone, Giulio Cerea, Giulia Pasello, Elisa Roca, Lorenzo Belluomini, Fabiana Letizia Cecere, Annalisa Guida, Anna Manzo, Vincenzo Adamo, Francesca Rastelli, Alessandra Bulotta, Fabrizio Citarella, Luca Toschi, Federica Zoratto, Diego Luigi Cortinovis, Rossana Berardi, Alessandro Follador, Annamaria Carta, Andrea Camerini, Flavio Salerno, Rosa Rita Silva, Editta Baldini, Alessio Cortellini, Matteo Brighenti, Matteo Santoni, Francesco Malorgio, Caterina Caminiti, Marcello Tiseo
PURPOSE: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. METHODS: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs)...
March 11, 2024: European Journal of Cancer
#37
JOURNAL ARTICLE
Brenda Leeneman, Nicolas S H Xander, W Edward Fiets, Wouter K de Jong, Nathalie E M Uyl, A N Machteld Wymenga, An K L Reyners, Carin A Uyl-de Groot
BACKGROUND: In the Netherlands, the clinical benefit of systemic anti-cancer treatments (SACTs) is assessed by the Committee for the Evaluation of Oncological Agents (cieBOM). For non-curative SACTs, the assessment is based on the hazard ratio (HR) for progression-free survival and/or overall survival (OS), and the difference in median survival. We evaluated the impact of different thresholds for effectiveness by reassessing the clinical benefit of SACTs. METHODS: We reassessed SACTs that were initially assessed by cieBOM between 2015 and 2017...
March 11, 2024: European Journal of Cancer
#38
JOURNAL ARTICLE
Silvia Stacchiotti, Gauthier Bouche, Ralf Herold, Pan Pantziarka, Kathrin Schuster, Roger Wilson, Francesco Pignatti, Bernd Kasper
Developing new drugs or generating evidence for existing drugs in new indications for ultra-rare cancers is complex and carries a high-risk of failure. This gets even harder in ultra-rare tumours, which have an annual incidence of 1 per 1,000,000 population or less. Here, we illustrate the problem of adequate evidence generation in ultra-rare tumours, using Alveolar Soft-Part Sarcomas (ASPS) - an ultra-rare sarcoma newly diagnosed in approximately 60 persons a year in the European Union - as an exemplar case showing challenges in development despite being potentially relevant for classes of agents...
March 11, 2024: European Journal of Cancer
#39
JOURNAL ARTICLE
Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, Meiyu Fang, Xiaoshi Zhang, Zhiguo Luo, Jing Chen, Gang Huang, Peng Zhang, Ying Cheng, Jiwei Liu, Jiyan Liu, Junping Zhang, Di Wu, Yu Chen, Xiaobiao Ma, Hongming Pan, Renbing Jiang, Xinlan Liu, Xiubao Ren, Hongqi Tian, Zhongwei Jia, Jun Guo, Lu Si
BACKGROUND: NRAS-mutant melanoma is an aggressive subtype with poor prognosis; however, there is no approved targeted therapy to date worldwide. METHODS: We conducted a multicenter, single-arm, phase II, pivotal registrational study that evaluated the efficacy and safety of the MEK inhibitor tunlametinib in patients with unresectable, stage III/IV, NRAS-mutant melanoma (NCT05217303). The primary endpoint was objective response rate (ORR) assessed by independent radiological review committee (IRRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1...
March 11, 2024: European Journal of Cancer
#40
REVIEW
Julian Kött, Noah Zimmermann, Tim Zell, Alessandra Rünger, Isabel Heidrich, Glenn Geidel, Daniel J Smit, Inga Hansen, Finn Abeck, Dirk Schadendorf, Alexander Eggermont, Susana Puig, Axel Hauschild, Christoffer Gebhardt
PURPOSE OF REVIEW: The role of Sentinel Lymph Node Biopsy (SLNB) is pivotal in the contemporary staging of cutaneous melanoma. In this review, we examine advanced molecular testing platforms like gene expression profiling (GEP) and immunohistochemistry (IHC) as tools for predicting the prognosis of sentinel lymph nodes. We compare these innovative approaches with traditional staging assessments. Additionally, we delve into the shared genetic and protein markers between GEP and IHC tests and their relevance to melanoma biology, exploring their prognostic and predictive characteristics...
March 8, 2024: European Journal of Cancer
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
